KA/EN
Register
Medicines reference
Search
Search
Product

Imomedine

Favourites

Medetomidine · Biotecsi Ltd

1 form: solution. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Dose Frequency Georgia
1 mg/ml, Solution · Cat Cat Sedation · Intravenous / Intramuscular / Subcutaneous: 0.05–0.15 ml/kgPremedication · Intravenous / Intramuscular / Subcutaneous: 0.01–0.03 ml/kg - Georgia Yes, veterinary
In force until 09 Apr 2029
Veterinary (National Food Agency)
In the register: იმომედინი
№ 000557
Verified on: 18 Oct 2026
1 mg/ml, Solution · Dog Dog Sedation · Intravenous / Intramuscular / Subcutaneous: 0.01–0.08 ml/kgPremedication · Intravenous / Intramuscular / Subcutaneous: 0.01–0.02 ml/kg - Georgia Yes, veterinary
In force until 09 Apr 2029
Veterinary (National Food Agency)
In the register: იმომედინი
№ 000557
Verified on: 18 Oct 2026
Details: pack, label wording, sources, registration

Imomedine 1 mg/ml, Solution

medetomidine hydrochloride 1 mg/ml, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Label-concordant restraint, procedural sedation/analgesia and premedication before injectable or inhalation anaesthesia in dogs
7.7/10
Good
vetman assessment

Imomedine

1 mg/ml, medetomidine hydrochloride 1 mg/ml, solution for injection
Assessed clinical scopeDog · Label-concordant restraint, procedural sedation/analgesia and premedication before injectable or inhalation anaesthesia in dogs · IV,IM,SC
Care settingMonitored veterinary sedation/anaesthesia with patient selection, accurate micro-volume dosing, cardiorespiratory and temperature monitoring, oxygen/ventilation and atipamezole reversal capability
vetman score 7.7/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 000557 · Verified on 18 Oct 2026

A credible, locally authorised and reversible medetomidine option with strong applicable evidence and excellent clinical utility in selected dogs. Its value depends on exact micro-volume dosing, cardiovascular discipline and ready reversal/support rather than casual sedation.

Regulatory and scientific credibility7.5/10

The exact 1 mg/ml 10 ml product has a current Georgian veterinary authorisation and a transparent manufacturer instruction covering composition, species, routes, doses, safety and storage. Current VMD/EU same-strength controls support dossier applicability, but the exact clinical instruction is not regulator-hosted and independent Imomedine outcome/pharmacovigilance data were not located.

Clinical efficacy8.5/10

Medetomidine has strong current regulatory and direct comparative clinical support for predictable restraint, sedation/analgesia and marked anaesthetic dose-sparing in selected dogs; response varies with agitation, size, route, dose and concomitant drugs.

Safety and tolerability6.5/10

The profile is well characterised and reversible, but very common bradycardia plus possible AV block, biphasic blood pressure, respiratory depression, hypoxia, hypothermia, emesis and rare pulmonary oedema/cardiac arrest require strict selection and active monitoring.

Clinical practicality8.5/10

IV/IM/SC flexibility, predictable onset, broad labelled dose bands, anaesthetic sparing and a specific antagonist fit equipped clinical workflows well. Very small volumes, weight/temperament adjustment, quiet onset, repeat-dose reassessment and monitored recovery demand precision.

Full-course cost-effectiveness-

A current Georgian clinic acquisition price and protocol-specific full-course comparator cost were not verified; price is excluded from the denominator.

Important safety and use flags

  • Do not use in pregnancy/lactation, shock, severe debility, severe cardiovascular or respiratory disease, liver/kidney dysfunction, gastric torsion or obstruction, diabetes mellitus, raised intraocular pressure or hypersensitivity.
  • Before dosing, examine the patient and record heart rate/rhythm, blood pressure, respiratory status, oxygenation and temperature. Continue ECG/physiologic monitoring through recovery; have oxygen and manual/mechanical ventilation available.
  • Expected alpha-2 physiology includes marked bradycardia or AV block and an initial blood-pressure rise followed by normal or low pressure. Do not judge perfusion from heart rate alone.
  • Vomiting can occur 5–15 minutes after injection and during recovery. Fast appropriately, protect the airway and do not offer food or water until swallowing is reliable.
  • Keep the patient warm during the procedure and for recovery; prolonged recovery can cause hypothermia. Lubricate exposed corneas during prolonged procedures, especially in cats.
  • Do not combine with sympathomimetic amines or trimethoprim-sulfonamide combinations. Other CNS depressants potentiate effect; reduce induction and maintenance anaesthetic doses and titrate to effect.
  • Do not reflexively treat expected medetomidine bradycardia with atropine or another anticholinergic. Simultaneous or subsequent anticholinergic use can worsen hypertension, tachycardia or arrhythmia; treat the patient and haemodynamics, not the number alone.
  • Have atipamezole 5 mg/ml and the original Imomedine dose documented. Canine reversal is five times the medetomidine dose in micrograms (the same ml volume at 5 mg/ml); awakening does not end cardiorespiratory monitoring.
  • Use a precisely graduated syringe for small volumes. The instruction describes single administration and allows a second injection only after 10–15 minutes if needed; reassess sedation depth, route, combinations and physiology before repeating.
  • Store at 15–25°C in the original pack, protected from light and moisture; do not freeze and discard 28 days after opening. Accidental self-injection can cause human sedation, bradycardia and blood-pressure change and requires urgent medical assessment.
Assessment sources
  1. Imomedine exact instruction2026
  2. VMD SPC 20262026
  3. Medeson UPD control2026
  4. Dog dexmedetomidine-butorphanol trial2013
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-concordant restraint, procedural sedation and premedication before injectable or inhalation anaesthesia in cats
7.2/10
Good
vetman assessment

Imomedine

1 mg/ml, medetomidine hydrochloride 1 mg/ml, solution for injection
Assessed clinical scopeCat · Label-concordant restraint, procedural sedation and premedication before injectable or inhalation anaesthesia in cats · IV,IM,SC
Care settingMonitored veterinary sedation/anaesthesia with patient selection, accurate micro-volume dosing, cardiorespiratory and temperature monitoring, oxygen/ventilation and atipamezole reversal capability
vetman score 7.2/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 000557 · Verified on 18 Oct 2026

A useful, locally authorised and reversible feline sedative/premedicant with convincing applicable evidence. Frequent emesis and important predictable alpha-2 cardiopulmonary/temperature effects keep monitoring and protocol discipline central.

Regulatory and scientific credibility7.5/10

The exact 1 mg/ml 10 ml product has a current Georgian veterinary authorisation and a transparent manufacturer instruction covering composition, species, routes, doses, safety and storage. Current VMD/EU same-strength controls support dossier applicability, but the exact clinical instruction is not regulator-hosted and independent Imomedine outcome/pharmacovigilance data were not located.

Clinical efficacy8.0/10

Current regulatory material and a blinded multicentre comparison support clinically useful feline restraint/sedation, combination anaesthesia and effective atipamezole reversal. Response and analgesic depth remain protocol-dependent, especially with ketamine or butorphanol.

Safety and tolerability5.5/10

Vomiting is very common and bradycardia/AV block, biphasic blood pressure, very slow respiration or apnoea, hypoxia and hypothermia are clinically important; severe circulatory failure has been reported. Reversal helps but does not replace airway, oxygenation and temperature care.

Clinical practicality8.0/10

Three labelled routes, single-injection use, anaesthetic sparing and atipamezole reversal are practical in an equipped clinic. Small volumes, frequent emesis, active warming, corneal protection and ketamine-aware reversal/recovery add meaningful but manageable work.

Full-course cost-effectiveness-

A current Georgian clinic acquisition price and protocol-specific full-course comparator cost were not verified; price is excluded from the denominator.

Important safety and use flags

  • Do not use in pregnancy/lactation, shock, severe debility, severe cardiovascular or respiratory disease, liver/kidney dysfunction, gastric torsion or obstruction, diabetes mellitus, raised intraocular pressure or hypersensitivity.
  • Before dosing, examine the patient and record heart rate/rhythm, blood pressure, respiratory status, oxygenation and temperature. Continue ECG/physiologic monitoring through recovery; have oxygen and manual/mechanical ventilation available.
  • Expected alpha-2 physiology includes marked bradycardia or AV block and an initial blood-pressure rise followed by normal or low pressure. Do not judge perfusion from heart rate alone.
  • Most cats may vomit 5–15 minutes after injection and some vomit again during recovery. Fast appropriately, protect the airway and do not offer food or water until swallowing is reliable.
  • Keep the patient warm during the procedure and for recovery; prolonged recovery can cause hypothermia. Lubricate exposed corneas during prolonged procedures, especially in cats.
  • Do not combine with sympathomimetic amines or trimethoprim-sulfonamide combinations. Other CNS depressants potentiate effect; reduce induction and maintenance anaesthetic doses and titrate to effect.
  • Do not reflexively treat expected medetomidine bradycardia with atropine or another anticholinergic. Simultaneous or subsequent anticholinergic use can worsen hypertension, tachycardia or arrhythmia; treat the patient and haemodynamics, not the number alone.
  • Have atipamezole 5 mg/ml and the original Imomedine dose documented. Feline reversal is 2.5 times the medetomidine dose in micrograms (half the ml volume at 5 mg/ml); after ketamine, respect protocol-specific delay and continue warming/monitoring.
  • Use a precisely graduated syringe for small volumes. The instruction describes single administration and allows a second injection only after 10–15 minutes if needed; reassess sedation depth, route, combinations and physiology before repeating.
  • Store at 15–25°C in the original pack, protected from light and moisture; do not freeze and discard 28 days after opening. Accidental self-injection can cause human sedation, bradycardia and blood-pressure change and requires urgent medical assessment.
Assessment sources
  1. Imomedine exact instruction2026
  2. VMD SPC 20262026
  3. Medeson UPD control2026
  4. Feline dexmedetomidine-atipamezole trial2006
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Medetomidine1 mg/ml
Formulation Type
Solution
Administration route
Intravenous, Intramuscular, Subcutaneous
Manufacturer
Biotecsi Ltd · Georgia
Manufacturer (register)
Biotecsi Ltd, Georgia
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1016, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 09 Apr 2029
Veterinary (National Food Agency)
In the register: იმომედინი
№ 000557
Verified on: 18 Oct 2026
 EU No
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified Exact-product label ranges: dogs — sedation/analgesia 10–80 micrograms/kg (0.01–0.08 ml/kg) and premedication 10–20 micrograms/kg (0.01–0.02 ml/kg); cats — sedation 50–150 micrograms/kg (0.05–0.15 ml/kg) and premedication 10–30 micrograms/kg (0.01–0.03 ml/kg). IV, IM or SC, selected by role and patient. The instruction describes a single dose and permits a second injection after 10–15 minutes if needed; reassess depth and physiology before any repeat. Use a precisely graduated syringe. Anaesthetic/CNS-depressant doses must be reduced to effect.
Cat
WeightSedation · Intravenous / Intramuscular / SubcutaneousPremedication · Intravenous / Intramuscular / Subcutaneous
Any weight 0.05–0.15 ml/kg 0.01–0.03 ml/kg
  • Sedation · Intravenous / Intramuscular / Subcutaneous (once): Moderate sedation 50-100 micrograms/kg (0.25-0.5 ml per 5 kg), deep sedation 100-150 micrograms/kg (0.5-0.75 ml per 5 kg), into a vein, a muscle or under the skin, once; the text gives 0.015-0.15 ml/kg overall. May be repeated after 10-15 minutes if needed. Fast for 12 hours before and keep warm; most cats vomit.
  • Premedication · Intravenous / Intramuscular / Subcutaneous (once): Premedication before injectable or inhalation anaesthesia: 10-30 micrograms/kg (0.05-0.15 ml per 5 kg) into a vein, a muscle or under the skin, once.
Source:
Imomedine exact instruction
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Imomedin 0.1% (medetomidine hydrochloride 1 mg/ml) solution for injection - exact manufacturer instruction
Biotecsi / Roqi, 2026
Dog
WeightSedation · Intravenous / Intramuscular / SubcutaneousPremedication · Intravenous / Intramuscular / Subcutaneous
Any weight 0.01–0.08 ml/kg 0.01–0.02 ml/kg
  • Sedation · Intravenous / Intramuscular / Subcutaneous (once): Sedation and analgesia for surgery, painful procedures and examinations: 10-80 micrograms/kg (0.1-0.8 ml per 10 kg) into a vein, a muscle or under the skin, once; light sedation 10-30, moderate to deep sedation with analgesia 30-80 micrograms/kg. Small breeds take the higher doses. May be repeated after 10-15 minutes if needed. Works best with ketamine or butorphanol. Fast for 12 hours before and keep warm; about 1 dog in 10 vomits.
  • Premedication · Intravenous / Intramuscular / Subcutaneous (once): Premedication before injectable or inhalation anaesthesia: 10-20 micrograms/kg (0.1-0.2 ml per 10 kg) into a vein, a muscle or under the skin, once.
Source:
Imomedine exact instruction
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Imomedin 0.1% (medetomidine hydrochloride 1 mg/ml) solution for injection - exact manufacturer instruction
Biotecsi / Roqi, 2026

Known Contraindications

  • Critical
    Do not use medetomidine in animals with heart failure.
  • Critical
    Do not use medetomidine in animals with impaired liver function.
  • Critical
    Do not use medetomidine in animals with impaired kidney function.
  • Critical
    Do not use medetomidine in animals with respiratory disease.
  • Critical (Dog)
    Do not use medetomidine in dogs under 12 weeks of age.
  • Warning
    Safety in pregnancy and lactation has not been established.
  • Warning
    Safety in pregnancy and lactation has not been established.
  • Caution
    Do not use in animals in shock, seriously debilitated, or stressed by extreme heat, cold or fatigue, nor together with sympathomimetic amines. Fast before use; keep the animal warm during the procedure and for 12 hours after; lubricate the eyes in long procedures. Anticholinergics given with or after medetomidine to treat bradycardia may harm the heart.

Known Drug Interactions

  • Minor warning Methadone + Medetomidine
    Methadone can potentiate analgesics, central nervous system depressants, and drugs that cause respiratory depression. Lower doses may be needed when these medicines are combined.
    Recommendation: Reduce doses when used in combination; monitor heart rate and respiration.
    Sources: Comfortan SPC

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (4 more) Hide additional products

Same therapeutic group 4

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗